Investor Presentation Q1-Q3 2020

71 Investor presentation First nine months of 2020 Novo Nordisk's ambition within cardiovascular disease In-licensing/acquisition of mid-stage assets CORVIDIA elsen Carolosu areceutics STATEN BIOTECHNOLOGY Accelerate internal pipeline At least one product launched between 2024-2028 targeting atherosclerotic cardiovascular disease or heart failure with a highly innovative, first to market product serving a significant unmet need in a large patient population Subcutaneous PCSK9i - successful phase 1 results Novo NordiskⓇ

View entire presentation